姜黄素与抗肿瘤药物联合应用的研究进展

doi:10.3969/j.issn.1000-1565.2024.01.007

摘要/Abstract

摘要： 联合用药能显著弥补单药使用的不足并能加快开发治疗复杂性疾病的新治疗方案.姜黄素是一种1,3-二酮类化合物,具有多种药理活性,其中抗肿瘤作用得到广泛关注.姜黄素能够抑制肿瘤细胞增殖、诱导肿瘤细胞凋亡等,具有毒性低、耐受性好等特点.研究发现:姜黄素与临床抗肿瘤药物联合应用具有一定的协同作用,能有效地抑制癌细胞生长,降低药物的毒副作用,减少药物剂量,达到增效减毒的效果.本文在细胞和实验动物水平上总结了姜黄素与抗肿瘤药物联合应用所产生的影响及可能的作用机制.

关键词: 姜黄素, 抗肿瘤药物, 联合用药, 抗肿瘤作用

Abstract: Drug combination therapy can significantly make up for the deficiency of single drug use and accelerate the development of new treatment options for the treatment of complex diseases.Curcumin is a 1,3-diketone compound with a variety of pharmacological effects, and its anti-tumor effect has received extensive attention. Curcumin can inhibit the proliferation of tumor cells and induce apoptosis of tumor cells. It has the characteristics of low toxicity and good tolerance. The study found that the combination of curcumin and clinical anti-tumor drugs has a certain synergistic effect, which can effectively inhibit the growth of cancer cells, decrease the toxic and side effects of drugs, reduce the dosage of drugs, and achieve the effect of synergistic attenuation. In this paper, the effects and possible mechanisms of the combined application of curcumin and anti-tumor drugs were summarized at the level of cells and experimental animals.

Key words: curcumin, antineoplastic drugs, drug combination, anti-tumor effect

中图分类号:

R962

刘文清,杨莎,刘明松,徐志栋. 姜黄素与抗肿瘤药物联合应用的研究进展[J]. 河北大学学报(自然科学版), 2024, 44(1): 50-59.

LIU Wenqing, YANG Sha, LIU Mingsong, XU Zhidong. Research progresses on the combined application of curcumin and antineoplastic drugs[J]. Journal of Hebei University(Natural Science Edition), 2024, 44(1): 50-59.

参考文献

[1] HE B, LU C, ZHENG G, et al. Combination therapeutics in complex diseases[J].J Cell Mol Med, 2016, 20(12): 2231-2240. DOI: 10.1111/jcmm.12930.
[2] 吴天怡,龚妍春,李资玲,等.抗癌纳米药物共递送系统的应用研究[J].材料导报,2020, 34(S1):516-522.
[3] DANIEL T M, BATES J H, DOWNES K A. History of tuberculosis[J]. Tuberculosis, 1994: 13-24. DOI: 10.1128/9781555818357.ch2.
[4] WANG Y, ZHANG X, HAN Y, et al. Efficacy of combined medication of nifedipine and magnesium sulfate on gestational hypertension and the effect on PAPP-A, VEGF, NO, Hcy and vWF[J]. Saudi J Biol Sci, 2019, 26(8): 2043-2047. DOI: 10.1016/j.sjbs.2019.08.012.
[5] KAVITT R T, LIPOWSKA A M, ANYANE-YEBOA A, et al. Diagnosis and treatment of peptic ulcer disease[J]. Am J Med, 2019, 132(4): 447-456. DOI: 10.1016/j.amjmed.2018.12.009.
[6] 国家药品监督管理局药品审评中心.关于发布《以临床价值为导向的抗肿瘤药物临床研发指导原则》的通告(2021年第46号)[EB/OL].https://www.cde.org.cn/main/news/viewInfoCommon/ef7bfde96c769308ad080bb7ab2f5.
[7] CHOU T C, TALALAY P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors[J]. Adv Enzyme Regul, 1984, 22: 27-55. DOI: 10.1016/0065-2571(84)90007-4.
[8] CHOU T C, MOTZER R J, TONG Y, et al. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design[J]. J Nati Cancer Inst, 1994, 86(20): 1517-1524. DOI: 10.1093/jnci/86.20.1517.
[9] KAUFMANN S H, PEEREBOOM D, BUCKWALTER C A, et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines[J]. J Nati Cancer Inst, 1996, 88(11): 734-741. DOI: 10.1093/jnci/88.11.734.
[10] GOPINATH H, KARTHIKEYAN K. Turmeric: A condiment, cosmetic and cure[J]. Indian J Dermatol Venereol Leprol, 2018, 84(1):16-21. DOI: 10.4103/ijdvl.IJDVL_1143_16.
[11] 任婧,张丹参,侯文书,等.姜黄素长循环脂质体的制备及表征[J].河北科技大学学报,2018, 39(6):532-539. DOI: 10.7535/hbkd.2018yx06008.
[12] ODOT J, ALBERT P, CARLIER A, et al. In vitro and in vivo anti-tumoral effect of curcumin against melanoma cells[J]. Int J Cancer, 2004, 111(3):381-387. DOI: 10.1002/ijc.20160.
[13] DU B Y, JIANG L P, XIA Q, et al. Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29[J]. Chemotherapy, 2006, 52(1):23-28. DOI: 10.1159/000090238.
[14] 宋鹏锦,韩啸,孙彩凤,等.新型肝动脉栓塞微球制剂的制备[J].河北大学学报(自然科学版),2022, 42(2):150-157. DOI: 10.3969/j.issn.10001565.2022.02.007.
[15] GIORDANO A, TOMMONARO G. Curcumin and Cancer[J]. Nutrients, 2019, 11(10):2376. DOI: 10.3390/nu11102376.
[16] 李海鹰,邱明恒,陈健,等.L-精氨酸基姜黄素衍生物的合成及抑菌性评价[J].河北大学学报(自然科学版),2021, 41(2):155-160. DOI: 10.3969/j.issn.10001565.2021.02.007.
[17] BHATT L, SEBASTIAN B, JOSHI V. Mangiferin protects rat myocardial tissue against cyclophosphamide induced cardiotoxicity[J]. J Ayurveda Integr Med, 2017, 8(2): 62-67. DOI: 10.1016/j.jaim.2017.04.006.
[18] ROSENBERG B, VANCAMP L, KRIGAS T. Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode[J]. Nature, 1965, 205(4972):698-699. DOI: 10.1038/205698a0.
[19] LOH G W, TING L S, ENSOM M H. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy[J]. Clin Pharmacokinet, 2007, 46(6):471-494. DOI: 10.2165/00003088-200746060-00002.
[20] 王悦璇,刘秀均.顺铂的作用靶点及耐药机制的研究进展[J].中国医药生物技术, 2020, 15(3):316-319. DOI: 10.3969/j.issn.1673-713X.2020.03.016.
[21] 夏叶舟,谭小武,曾赛丽.姜黄素联合顺铂对肺癌 A549 细胞侵袭转移的影响及其可能机制[J].中国呼吸与危重监护杂志,2017, 16(6):581-585. DOI: 10.7507/1671-6205.201706015.
[22] CHENG Y, ZHAO P X, WU S P, et al. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma[J]. Int J Pharm, 2018, 545(1-2): 261-273. DOI: 10.1016/j.ijpharm.2018.05.007.
[23] SANDHIUTAMI N M D, AROZAL W, LOUISA M, et al. Curcumin nanoparticle enhances the anticancer effect of cisplatin by inhibiting PI3K/AKT and JAK/STAT3 pathway in rat ovarian carcinoma induced by DMBA[J]. Front Pharmacol, 2021, 11:603235. DOI: 10.3389/fphar.2020.603235.
[24] KUMAR P, BARUA C C, SULAKHIYA K, et al. Curcumin ameliorates cisplatin-induced nephrotoxicity and potentiates its anticancer activity in SD rats: potential role of curcumin in breast cancer chemotherapy[J]. Front Pharmacol, 2017, 8:132. DOI: 10.3389/fphar.2017.00132.
[25] ABDULLAH S, EL HADAD S, ALDAHLAWI A. The development of a novel oral 5-Fluorouracil in-situ gelling nanosuspension to potentiate the anticancer activity against colorectal cancer cells[J]. Int J Pharm, 2022, 613:121406. DOI: 10.1016/j.ijpharm.2021.121406.
[26] 孙维彤,陈倩倩,张娜,等.5-氟尿嘧啶前体药物研究进展[J].生命的化学,2014, 34(02): 269-274. DOI: 10.13488/j.smhx.20140222.
[27] VALENCIA-LAZCANO AA, HASSAN D, POURMADADI M, et al. 5-Fluorouracil nano-delivery systems as a cutting-edge for cancer therapy[J]. Eur J Med Chem, 2023, 246: 114995. DOI: 10.1016/j.ejmech.2022.114995.
[28] 梁婧,皮超,冯婷,等.姜黄素/5-FU 对肝癌细胞的生长抑制作用[J].时珍国医国药,2018, 29(2):272-274. DOI:10.3969/j.issn.1008-0805.2018.02.006.
[29] 秦文兵,李瑞佳,张月丽.姜黄素对食管癌细胞中 5-FU 化疗敏感性的影响[J].中成药,2023, 45(3):960-964. DOI: 10.3969/j.issn.1001-1528.2023.03.047.
[30] PENDLETON E G, JAMASBI R J, GEUSZ M E. Tetrahydrocurcumin, curcumin, and 5-Fluorouracil effects on human esophageal carcinoma cells[J]. Anticancer Agents Med Chem, 2019, 19(8):1012-1020. DOI: 10.2174/1871520619666190116141448.
[31] BIDWELL G L 3rd, FOKT I, PRIEBE W, et al. Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin[J]. Biochem Pharmacol, 2007, 73(5):620-631. DOI: 10.1016/j.bcp.2006.10.028.
[32] 杨学礼,张红蕾,杨瑜涛,等.HPLC 法测定 DNA 纳米运输系统载药阿霉素的含量[J].药物分析杂志,2019, 39(7):1239-1243. DOI: 10.16155/j.0254-1793.2019.07.10.
[33] JAWAD B, POUDEL L, PODGORNIK R, et al. Molecular mechanism and binding free energy of doxorubicin intercalation in DNA[J]. Phys Chem Chem Phys, 2019, 21(7):3877-3893. DOI: 10.1039/c8cp06776g.
[34] PETER S, ALVEN S, MASEKO R B, et al. Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review[J]. Molecules, 2022, 27(14):4478. DOI: 10.3390/molecules27144478.
[35] 王磊,柯红,王一羽,等.联合应用阿霉素和姜黄素增强人白血病细胞株HL-60对阿霉素的敏感性[J].时珍国医国药,2009, 20(2): 418-420.
[36] 周思颖,张思杰,徐寒子,等.姜黄素脂质体通过调节 miRNA 的表达改变乳腺癌细胞对阿霉素的化疗敏感性[J].南京中医药大学学报, 2018, 34(3):312-317. DOI: 10.14148/j.issn.1672-0482.2018.0312.
[37] GUO W, SONG Y Y, SONG W T, et al. Co-delivery of doxorubicin and curcumin with polypeptide nanocarrier for synergistic lymphoma therapy[J]. Sci Rep, 2020, 10(1):7832. DOI: 10.1038/s41598-020-64828-1.
[38] ZHAO X J, CHEN Q, LIU W, et al. Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer[J]. Int J Nanomedicine, 2015, 10:257-270. DOI: 10.2147/IJN.S73322.
[39] ZHU L Y, CHEN L Q. Progress in research on paclitaxel and tumor immunotherapy[J]. Cell Mol Biol Lett, 2019, 24: 40. DOI: 10.1186/s11658-019-0164-y.
[40] AHMED KHALIL A, RAUF A, ALHUMAYDHI F A, et al. Recent developments and anticancer therapeutics of paclitaxel: an update[J]. Curr Pharm Des, 2022, 28(41): 3363-3373. DOI: 10.2174/1381612829666221102155212.
[41] 王煦鑫,朱华结.手性化合物立体结构鉴定中的若干关键共性科学问题探讨[J].高等学校化学学报,2021, 42(6):1685-1693. DOI: 10.7503/cjcu20200726.
[42] YANG Y H, MAO J W, TAN X L. Research progress on the source, production, and anti-cancer mechanisms of paclitaxel[J]. Chin J Nat Med, 2020, 18(12): 890-897. DOI: 10.1016/S1875-5364(20)60032-2.
[43] 刘冠媛,梁华茂,曾新红,等.紫杉醇和姜黄素联用对人卵巢癌细胞系 OC_3的抑制作用[J].山东大学学报(医学版), 2004, 42(3): 325-7+31.
[44] GANTA S, DEVALAPALLY H, AMIJI M. Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation[J]. J Pharm Sci, 2010, 99(11):4630-4641. DOI: 10.1002/jps.22157.
[45] 刘敏,张君,李俊福,等.姜黄素联合紫杉醇对人口腔鳞癌细胞的增殖抑制及凋亡诱导作用[J].上海口腔医学, 2016, 25(5):538-541.
[46] 齐瑞芳,石瑞丽,吕军,等.姜黄素联合紫杉醇在体内外可协同降低乳腺癌MDA-MB-231细胞迁移能力并降低MMP9表达[J].中药药理与临床, 2016, 32(01):83-85. DOI: 10.13412/j.cnki.zyyl.2016.01.023.
[47] CALAF G M, PONCE-CUSI R, CARRIÓN F. Curcumin and paclitaxel induce cell death in breast cancer cell lines[J]. Oncol Rep, 2018, 40(4):2381-2388. DOI: 10.3892/or.2018.6603.
[48] ZHONG L, LI Y S, XIONG L, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives[J]. Signal Transduct Target Ther, 2021, 6(1):201. DOI: 10.1038/s41392-021-00572-w.
[49] 胡宏祥,王学清,张华,等.分子靶向抗肿瘤药物的作用机制及临床研究进展[J].药学学报, 2015, 50(10): 1232-1239.DOI:10.16438/j.0513-4870.2015.10.024.
[50] XIA S J, PAN Y, LIANG Y L, et al. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma[J].EBioMedicine, 2020, 51:102610. DOI: 10.1016/j.ebiom.2019.102610.
[51] 吴紫阳,于之恒,王志妍,等.吉非替尼个体差异指标的临床研究现状[J].中国临床药理学杂志,2020, 36(4):458-461. DOI: 10.13699/j.cnki.1001-6821.2020.04.021.
[52] 胡博,孙超,孙鼎,等.姜黄素纳米粒(NanoCurc~(TM))联合索拉非尼对肝细胞癌(HCC)的协同抑制作用[J].复旦学报(医学版), 2014, 41(2):143-148. DOI: 10.3969/j.issn.1672-8467.2014.02.001.
[53] 朱怡卿,王芳.脂质体姜黄素联合索拉非尼对人肝癌 Huh7细胞的抑制作用[J].中国医学物理学杂志, 2018, 35(11):1324-1328. DOI: 10.3969/j.issn.1005-202X.2018.11.016.
[54] 常明向,吴梅梅,李瀚旻.姜黄素联合索拉非尼增强抑制肝癌细胞 HepG-2 的作用及其机制[J].中西医结合肝病杂志, 2016, 26(5):277-280. DOI: 10.3969/j.issn.1005-0264.2016.05.008.
[55] JIN X, WANG J, SHEN H F, et al. Curcumin co-treatment ameliorates resistance to gefitinib in drug-resistant NCI-H1975 lung cancer cells[J]. J Tradit Chin Med, 2017, 37(3): 355-360.
[56] CHEN P, HUANG H P, WANG YI, et al. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death[J]. J Exp Clin Cancer Res, 2019, 38(1):254. DOI: 10.1186/s13046-019-1234-8. (